Awakn Life Sciences Corp.
AWKN
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -89.44% | -91.34% | -92.48% | -94.29% | -57.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.44% | -91.34% | -92.48% | -94.29% | -57.98% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -13.55% | 121.53% | 700.00% | 124.58% | 112.05% |
| SG&A Expenses | -52.99% | -50.11% | -25.19% | -30.32% | -38.17% |
| Depreciation & Amortization | 7.87% | 38.89% | 31.19% | -88.57% | -93.28% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.98% | -43.57% | -22.90% | -40.98% | -54.98% |
| Operating Income | 45.45% | 44.86% | 24.76% | 39.89% | 53.36% |
| Income Before Tax | 17.86% | 15.24% | 3.07% | 40.77% | 68.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.86% | 15.24% | 3.07% | 40.77% | 68.15% |
| Earnings from Discontinued Operations | 111.65% | 109.41% | 94.87% | 58.77% | -91.67% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 2.12% | -61.43% |
| Net Income | 65.20% | 66.26% | 51.79% | 47.43% | 44.23% |
| EBIT | 45.45% | 44.86% | 24.76% | 39.89% | 53.36% |
| EBITDA | 44.35% | 43.89% | 21.42% | 36.61% | 53.13% |
| EPS Basic | 74.05% | 74.05% | 60.68% | 54.38% | 43.43% |
| Normalized Basic EPS | 44.44% | 41.10% | 16.74% | 50.98% | 66.94% |
| EPS Diluted | 74.05% | 74.05% | 60.68% | 54.38% | 43.43% |
| Normalized Diluted EPS | 44.44% | 41.10% | 16.74% | 50.98% | 66.94% |
| Average Basic Shares Outstanding | 29.47% | 29.55% | 26.82% | 16.37% | 3.35% |
| Average Diluted Shares Outstanding | 29.47% | 29.55% | 26.82% | 16.37% | 3.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |